Opinion: How biopharma companies can keep ‘feeding the beast’ in the time of coronavirus
My colleagues and I lead and support the finance function of more than 160 biopharma companies. This gives us an inside view of the conversations and questions dominating the leadership teams of life science firms over the past few weeks as the Covid-19 pandemic has changed just about every aspect of the U.S. and global economies.
Common themes have emerged, but none are more pervasive than “feeding the beast.”
